Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-dose rituximab with autologous-SCT promising for relapsed/refractory DLBCL

Key clinical point: Overall and progression-free survival were better with high-dose rituximab compared to controls.

Major finding: Overall survival in the HD-R group compared to the control group was 80.1% vs. 50.0%, respectively, P = .035).

Study details: A prospective, nonrandomized comparison of 22 DLBCL patients treated with high-dose rituxumab to 20 control patients.

Disclosures: The work was supported by Chinese government agencies. The authors reported that they had no conflicts.

Citation:

First author et al. Medicina Clinica. 2020; doi.org/10.1016/j.medcli.2019.11.009.